Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management ...

Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

According to a market report by Lucintel, the future of the global bladder cancer diagnostic market looks promising with ...

The positive predictive value (PPV) for Bladder EpiCheck was 67.4%, with a negative predictive value (NPV) for both overall and HG disease of 99.6%. WLC demonstrated a PPV of 74%, an NPV of 96.3%, and ...

AUA annual meeting featured the 4 th annual IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Bernard Bochner, with a debate between Drs. Sia ...

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its enterprise imaging solution as a cloud service, Sectra One Cloud, to a US cancer center under a new ...

Asetek A/S' board of directors has on April 28, 2025, decided to grant stock options and RSU's (Restricted Stock Units) to key employees in the Company and a subsidiary. The decision is made in ...